Charles River Laboratories International (CRL) closed at $337.52 on November 6, 2026, up 7.8% from the previous close, on volume of 909,599 shares (30-day average 1,110,493).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Strangle or Risk Reversal | 20-Nov-26330 P : 400 C | 3,218 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Charles River to acquire Frontage's bioanalysis and DMPK operations for $470M cash
Seeking Alpha News (Mon, 9-Nov 6:40 AM ET)
Charles River Labs to Acquire Frontage Bioanalysis Operations
TipRanks (Mon, 9-Nov 6:30 AM ET)
Charles River Laboratories to Acquire Frontage's Bioanalysis and DMPK Businesses
Business Wire (Mon, 9-Nov 6:10 AM ET)
Charles River Laboratories Earnings Call Signals Strong Recovery
TipRanks (Sun, 8-Nov 7:28 PM ET)
Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focus
Seeking Alpha News (Sun, 8-Nov 9:05 AM ET)
S&P 500 gainers: Today’s top performers ranked by Quant
Seeking Alpha News (Fri, 6-Nov 1:15 PM ET)
TipRanks (Thu, 5-Nov 6:20 PM ET)
RBC Capital Remains a Buy on Charles River Labs (CRL)
TipRanks (Thu, 5-Nov 7:37 AM ET)
Charles River Labs (CRL) Receives a Buy from Barclays
TipRanks (Thu, 5-Nov 3:37 AM ET)
Market Chameleon (Wed, 4-Nov 4:02 AM ET)
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
Charles River Laboratories International trades on the NYSE stock market under the symbol CRL.
As of November 6, 2026, CRL stock price climbed to $337.52 with 909,599 million shares trading.
CRL has a beta of 1.50, meaning it tends to be more sensitive to market movements. CRL has a correlation of 0.13 to the broad based SPY ETF.
CRL has a market cap of $17.26 billion. This is considered a Large Cap stock.
Last quarter Charles River Laboratories International reported $983 million in Revenue and $3.09 earnings per share. This beat revenue expectation by $23 million and exceeded earnings estimates by $.12.
In the last 3 years, CRL traded as high as $379.63 and as low as $91.86.
The top ETF exchange traded funds that CRL belongs to (by Net Assets): VTI, VOO, VB, RSP, VBR.
CRL has outperformed the market in the last year with a price return of +97.5% while the SPY ETF gained +10.8%. CRL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +27.1% and -2.3%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
CRL support price is $302.27 and resistance is $323.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRL shares will trade within this expected range on the day.
